https://www.selleckchem.com/pr....oducts/CP-690550.htm
Presence of daily headache pattern was negatively associated with response, (56% response vs. 90% without daily headache, p = 0.0003). There was no association between age, gender, presence of medication overuse or number of previously tried prophylactic treatments and response to erenumab. 43% of patients reported at least one adverse effect, most commonly constipation (26%); treatment was discontinued in 3 patients due to adverse effects. Erenumab was an effective treatment for chronic migraine in this treatment resistant population
Мне нравится
Комментарий
Перепост
